IPO
Ultragenyx Pharmaceutical Inc. announced that it will host a conference call on Tuesday, February 19, 2019 at 5pm ET to discuss its financial results and corporate update for the fourth quarter and the year ended December 31, 2018.
Estimated enterprise value of EUR 160 million compared to current EV of EUR 121 million
Karolinska Development’s portfolio company OssDsign announces today the closing of a private placement of SEK 64 million.
MDxHealth SA, announced that it received on February 7, 2019 the following notification of significant shareholdings in accordance with the Belgian Act of May 2, 2007 on the disclosure of important participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions.
Auris Medical Holding AG announced its receipt of notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company did not meet Nasdaq’s January 28, 2019 deadline to regain compliance with Nasdaq Listing Rule 5550(a)(2) due to the bid price per share for its common shares remaining below $1.00.
Medtronic plc announced that it will report financial results for the third quarter of fiscal year 2019 on Tuesday, February 19 , 2019.
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Gossamer Bio has been the poster child for biotech companies struggling with IPO launches during the shutdown.
BioArctic AB to publish the company’s Full Year Report for the period January – December 2018 on Thursday, February 14, 2019 at 08:00 a.m. CET.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
PRESS RELEASES